MRMarc A. Riedl

Marc A. Riedl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marc A. Riedl has a total of 915 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hemostatic function remains unaltered following therapeutic factor XIIa inhibition with garadacimab

    by Danny M. Cohn, Henriette Farkas, Marc A. Riedl, Harsha Shetty, John-Philip Lawo, Maressa Pollen, H. Henry Li

  • Open Access

    Correction: Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study

    by Gil Yosipovitch, Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, Tara Raftery, Irina Pivneva, Jason Doran, Arthur Voegel, James Signorovitch, Marc A. Riedl

  • Open Access

    Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes

    by Marc A. Riedl, Danny M. Cohn, Markus Magerl, Henriette Farkas, Emel Aygören-Pürsün, Aleena Banerji, Jonathan A. Bernstein, Alvin H. Schmaier, Evangelia Pardali, Anne Lesage, et al.

    Bradykinin is a nonapeptide of the kinin family with vasoactive and proinflammatory activities. While generation of kinins is mainly driven by activation of the contact system and plasma or tissue kallikreins, additional independent cascades contribute to their formation. Kinins mediate their effects through the constitutively expressed bradykinin B2 receptor and the inducible bradykinin B1 receptor. Bradykinin is the most studied kinin peptide mainly due to its potential role in the vascular system and exerts its effects mainly via the bradykinin B2 receptor. Kinins have been implicated in the pathogenesis of multiple types of angioedema as well as of various conditions, such as allergic mast cell-mediated skin diseases, cardiovascular and respiratory pathologies. This review summarizes our current knowledge of the biology, regulation, and functions of kinins and their receptors as well the emerging evidence on the various mechanisms involved in bradykinin formation and their relevance in disease pathogenesis. The review focuses on the clinical evidence on the roles of bradykinin and of the bradykinin B2 receptor in various conditions, and the potential to develop novel strategies targeting the bradykinin B2 receptor for management of bradykinin-mediated diseases.

  • Open Access

    Social Determinants of Health in Newly Diagnosed Hereditary Angioedema and Their Impact on Healthcare Resource Utilization Outcomes

    by Alan P. Baptist, J. Allen Meadows, Marc A. Riedl, Tigwa Davis, Scott B. Robinson, Yecheng Huang, Iman Mohammadi, Krystal Sing, Daniel Fox, Bob G. Schultz, et al.

  • Open Access

    Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study

    by Gil Yosipovitch, Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, Tara Raftery, Irina Pivneva, Jason Doran, Arthur Voegel, James Signorovitch, Marc A. Riedl

    Introduction Chronic spontaneous urticaria (CSU) is a skin disorder for which short-course systemic corticosteroids are recommended only as rescue medication during acute exacerbations. Here, we describe real-world corticosteroid use, adverse events (AEs) occurring post-corticosteroid initiation, and health care resource utilization (HCRU) of patients with CSU in the USA. Methods This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023). Only prescription and non-antihistamine claims were included in the analysis of treatment patterns. In the AE and HCRU analyses, patients were stratified into five cohorts on the basis of total days of systemic corticosteroid supply as a proxy for duration of use: ≤ 31 days, > 31 to ≤ 60 days, > 60 days, ≥ 90 days (subcohort of > 60 days), and non-corticosteroid users. Results Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines. The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use. More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use. Conclusions Patients with CSU who were prescribed corticosteroids reported a higher proportion of AEs and more frequent HCRU than those who were not. These trends in AEs and HCRU were more prominent with increasing duration of corticosteroid use.


  • Top Cited Papers
    Open Access

    Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial

    by Marcus Maurer, Marcin Stobiecki, Anna Valerieva, Roman Hakl, Maria T Staevska, Laurence Bouillet, Aurélie Du-Thanh, Aharon Kessel, Sorena Kiani-Alikhan, Markus Magerl, et al.


  • Top Cited Papers
    Open Access

    Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial

    by Emel Aygören-Pürsün, Marcin Stobiecki, Anna Valerieva, Mauro Cancian, Mark Gompels, Sofia Grigoriadou, Sorena Kiani-Alikhan, Tamar Kinaciyan, William H Yang, John Anderson, et al.


  • Open Access

    Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

    by Marc A. Riedl, Jonathan A. Bernstein, Joshua S. Jacobs, Timothy Craig, William R. Lumry, H. James Wedner, Aleena Banerji, Selina Gierer, Andrew Smith, Michael E. Manning, et al.

    Background: Donidalorsen is an antisense oligonucleotide designed to reduce plasma prekallikrein in patients with hereditary angioedema (HAE). The Switch cohort of the OASISplus study (NCT05392114) evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Methods: This study enrolled patients with HAE aged ≥ 12 years previously on stable doses of an LTP (lanadelumab, berotralstat, C1 inhibitor). Patients directly switched from an LTP to donidalorsen 80 mg administered subcutaneously once every 4 weeks. Endpoints included incidence and severity of treatment‐emergent adverse events (TEAEs; primary endpoint), monthly HAE attack rate, Angioedema Quality of Life (AE‐QoL), and Angioedema Control Test (AECT) measured at baseline and Week 52. Results: Sixty‐five patients enrolled, and 54 (83.1%) completed 1 year. Eleven (16.9%) patients discontinued treatment during the first year, and one discontinued treatment after 1 year. Donidalorsen reduced HAE attack rates from baseline on the prior LTP by 67.6% over 52 weeks. Fifty‐six of 64 (87.5%) dosed patients experienced a TEAE; most reported mild to moderate events. The most common treatment‐related TEAEs were injection‐site erythema (10.9%) and injection‐site pruritus (10.9%). One patient had a serious adverse event that was not treatment‐related. AE‐QoL total score improved by 12.2 points (clinically meaningful ≥ 6 points) from baseline to Week 52, and 90.4% of patients had well‐controlled disease (AECT ≥ 10) at Week 52. Conclusion: In patients who switched from another LTP, donidalorsen was well tolerated and improved long‐term HAE attack rates, quality of life, and disease control.


  • Top Cited Papers
    Open Access

    The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

    by Torsten Zuberbier, Zainab AbdulHameed Ansari, Amir H. Abdul Latiff, M. M. Abuzakouk, Maria Socorro Agcaoili‐De Jesus, Rosana C. Agondi, Mona Al‐Ahmad, Abdullah A. Alangari, H. Alhameli, Cesar D. Alonso Bello, et al.

    This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.


  • Top Cited Papers
    Open Access

    The International/Canadian hereditary angioedema guideline

    by Stephen Betschel, Karen Binkley, Rozita Borici-Mazi, Hugo Chapdelaine, Jacques Hébert, Amin Kanani, Paul K. Keith, Gina Lacuesta, Susan Waserman, William Yang, et al.

    This update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline broadens its focus to include the management of patients with HAE worldwide, building on its established international framework. It has been developed through a collaboration of Canadian and international HAE experts and patient groups, coordinated by the Canadian Hereditary Angioedema Network. The objective is to provide evidence-based recommendations, using the Grading of Recommendations Assessment, Development and Evaluation system, for the management of patients with HAE. These include recommendations for the treatment of attacks, short-term prophylaxis, and long-term prophylaxis, as well as recommendations for self-administration, individualized therapy, health-related quality of life, and comprehensive care. New to the 2024 edition are specific recommendations for the treatment of angioedema attacks in individuals with HAE who are breastfeeding/lactating, as well as a dedicated section on shared decision-making. HAE results in spontaneous and often unpredictable attacks of painful swelling, typically affecting the extremities, bowel mucosa, genitals, face, and upper airway. These attacks are associated with significant functional impairment, reduced health-related quality of life, and in the case of laryngeal attacks, a high risk of mortality. Managing HAE is complex, and patient care in Canada, similar to many other countries, remains inconsistent and suboptimal. Care delivery lags behind nations that have implemented more structured management models for HAE, and offer broader access to a wider range of approved therapies. This guideline is intended to be used to optimize HAE management, highlight the importance of individualized care, and provide guidance to healthcare providers, policymakers, patients, and advocates. Primary target users include healthcare providers who are managing patients with HAE, as well as emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, pediatricians, hematologists, dermatologists, and gynecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.